611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Mixing Marijuana With Opioids May Not Be Good for Mental HealthLarge Opioid Rx After Heart, Lung Surgery Often Leads to Misuse: StudyWhy Diet Sodas Aren't the Answer for Your Sugary Drink CravingsTB Cases Drop Among the Young, But Racial Disparities PersistCases of Lung Injury Tied to Vaping Keep RisingFish Oil Not a Magic Pill Against DiabetesFacing Up to a Lesser Known Form of Migraine PainDirty Air Is Deadly, Global Study ConfirmsSmoggy Air Might Contribute to Macular DegenerationMore Antibiotics, Higher Odds for Colon Cancer?The Merits of Physical TherapyVaping Constricts Blood Vessels, Raising Heart, Lung ConcernsWhen Does Heart Health Return to Normal After Quitting Smoking?New Antibiotic Approved for Community-Acquired Bacterial PneumoniaImplant Approved to Improve Symptoms in Advanced Heart Failure'No Quick Fix' for A-Fib, But Cardiologist Says You Can Help Prevent ItAHA News: Why Do Women Get Statins Less Frequently Than Men?'Dr. Google' Helps Some Patients Diagnose a Rare DiseaseHealth Tip: Recognizing a Staph InfectionIs Dairy Fat Different?CDC Recommends Catch-Up HPV Vaccination for Young AdultsHow to Relieve Dry, Irritated EyesPretomanid Approved for Treatment of Drug-Resistant TBAHA News: Tiring Easily May Warn of Future Heart TroubleAmerica's Obesity Epidemic May Mean Some Cancers Are Striking SoonerHeavy Smog as Bad as Pack-a-Day Smoking for LungsConcussed NFL Players Sidelined for Much Longer NowadaysHormone Therapy for Prostate Cancer Might Harm the Heart: StudyObesity and 'Spare Tire' Raise Hispanics' Odds for Early DeathAHA News: Protein Made During Long Workouts May Warn of Heart ProblemsHow to Help Your Heart Weather Extreme HeatHealth Threats Don't End for Some Sepsis SurvivorsHeat Waves Brought by Climate Change Could Prove Deadly for Kidney PatientsHealth Tip: Avoiding AnemiaAre You Still Putting Off Colon Cancer Screening?Tips for Preventing DiverticulitisFDA Reports More Seizures Among VapersKids Getting Too Many Opioids After TonsillectomyCan Major Surgeries Cause a Long-Term 'Brain Drain'?How Much Coffee Is Too Much for Migraine Sufferers?Steady Stream of Lesser Head Hits in Football Can Still Damage BrainDon't Sweat It: Hyperhydrosis Can Be TreatedFast-Food Joints on Your Way to Work? Your Waistline May WidenAdults Need Vaccines, TooHealth Tip: Managing Arthritis of the Hands'Selfies' Might Someday Track Your Blood PressureIn Heat Waves, Fans May Do More Harm Than GoodSmoking Creates Long-Lasting Risk for Clogged Leg ArteriesFootball Head Trauma Linked Again to Long-Term Brain DamageDrug Approved to Treat Tenosynovial Giant Cell Tumor
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

FDA Approves First Gene Therapy for Spinal Muscular Atrophy


HealthDay News
Updated: May 28th 2019

new article illustration

TUESDAY, May 28, 2019 (HealthDay News) -- The first gene therapy has been approved to treat children younger than 2 years with spinal muscular atrophy (SMA), the U.S. Food and Drug Administration announced Friday.

Zolgensma (onasemnogene abeparvovec-xioi), an adeno-associated virus vector-based gene therapy, targets the cause of SMA by delivering a fully functional copy of the human SMN1 gene into the target motor neuron cells. According to the FDA, a one-time intravenous administration of the drug yields expression of the SMN protein in a child's motor neurons, which improves movement, function, and survival. Dosing is based on patient weight, with a recommended dosage of 1.1 × 1.014 vector genomes per kilogram of body weight. Zolgensma is administered as an intravenous infusion for 60 minutes.

Approval was based on two clinical trials, one ongoing. The completed clinical trial involved 36 children with infantile-onset SMA who were 2 weeks to 8 months old at study initiation. In the ongoing clinical trial, which initially included 21 patients, the 19 remaining patients are 9.4 to 18.5 months old. These patients have demonstrated significant improvement in reaching developmental motor milestones compared with the natural history of patients with infantile-onset SMA.

Commonly reported side effects include elevated liver enzymes and vomiting. A boxed warning included with the prescribing information indicates the risk for acute serious liver injury and warns that patients with preexisting liver impairment may be at higher risk. Before initiating treatment with Zolgensma and for at least three months after administration, clinicians should assess patients' liver function through clinical examination and laboratory testing. Patients should also be administered an oral corticosteroid before and after Zolgensma infusion; because certain vaccines are contraindicated for patients taking a corticosteroid, caregivers should consult with clinicians to determine if adjustments to the child's immunization schedule are necessary.

Approval of Zolgensma was granted to AveXis.

More Information